Sarcopenia Does Not Impact the Outcome of Patients with Multiple Myeloma Consolidated with Autologous Hematopoietic Stem Cell Transplantation.

IF 2 4区医学 Q3 ONCOLOGY

Chemotherapy Pub Date : 2024-01-01 Epub Date: 2024-02-08 DOI:10.1159/000535692

Ombretta Annibali, Annamaria Altomare, Valeria Tomarchio, Giulia Rocchi, Carlo Augusto Mallio, Maria Antonietta Tafuri, Bruno Beomonte Zobel, Bruno Vincenzi, Michele Pier Luca Guarino, Luigi Rigacci, Giuseppe Avvisati

{"title":"Sarcopenia Does Not Impact the Outcome of Patients with Multiple Myeloma Consolidated with Autologous Hematopoietic Stem Cell Transplantation.","authors":"Ombretta Annibali, Annamaria Altomare, Valeria Tomarchio, Giulia Rocchi, Carlo Augusto Mallio, Maria Antonietta Tafuri, Bruno Beomonte Zobel, Bruno Vincenzi, Michele Pier Luca Guarino, Luigi Rigacci, Giuseppe Avvisati","doi":"10.1159/000535692","DOIUrl":null,"url":null,"abstract":"Introduction: Sarcopenia has been associated with chronic diseases and cancer. The aim of this study was to evaluate sarcopenia in multiple myeloma patients undergoing autologous stem cell transplantation.Methods: In 68 eligible patients, measurement of skeletal muscle area (cm2) on computed tomography scans at the level of the L3 vertebra (L3 SMI) was performed.Results: 37 (54%) patients were categorized as sarcopenic: 26 males with L3 SMI values <52.4 cm2/m2, and 11 women with L3 SMI values <38.9 cm2/m2. The majority of sarcopenic patients included were older than 60 years (69%, p = 0.0005), with BMI <25 (75%; p = 0.0000). A significant association was found between sarcopenia and Sorror score value >1 (p = 0.02).Conclusions: The Kaplan-Meier curve showed a median OS of 73.5 months for non-sarcopenic patients versus 86.5 months for sarcopenic patients, suggesting that sarcopenia is not an independent prognostic factor in this cohort of patients. Further prospective studies are needed to confirm these data.","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000535692","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Sarcopenia has been associated with chronic diseases and cancer. The aim of this study was to evaluate sarcopenia in multiple myeloma patients undergoing autologous stem cell transplantation.

Methods: In 68 eligible patients, measurement of skeletal muscle area (cm2) on computed tomography scans at the level of the L3 vertebra (L3 SMI) was performed.

Results: 37 (54%) patients were categorized as sarcopenic: 26 males with L3 SMI values <52.4 cm2/m2, and 11 women with L3 SMI values <38.9 cm2/m2. The majority of sarcopenic patients included were older than 60 years (69%, p = 0.0005), with BMI <25 (75%; p = 0.0000). A significant association was found between sarcopenia and Sorror score value >1 (p = 0.02).

Conclusions: The Kaplan-Meier curve showed a median OS of 73.5 months for non-sarcopenic patients versus 86.5 months for sarcopenic patients, suggesting that sarcopenia is not an independent prognostic factor in this cohort of patients. Further prospective studies are needed to confirm these data.

查看原文本刊更多论文

多发性母细胞瘤患者接受自体造血干细胞移植后，肉骨减少症不会影响治疗效果。

肌肉疏松症与慢性疾病和癌症有关。本研究旨在评估接受自体干细胞移植的多发性骨髓瘤患者的肌肉疏松症。在 68 名符合条件的患者中，测量了 L3 椎骨水平计算机断层扫描（L3-SMI）上的骨骼肌面积（平方厘米）。37名（54%）患者被归类为肌肉疏松：26名男性患者的L3-SMI值小于52.4 cm2/m2，11名女性患者的L3-SMI值小于38.9 cm2/m2。大部分肌无力患者年龄超过 60 岁（69%，P=0.0005），体重指数为 1（P=0.02）。卡普兰-迈耶曲线显示，非肌肉疏松患者的中位生存期为 73.5 个月，而肌肉疏松患者的中位生存期为 86.5 个月，这表明在这组患者中，肌肉疏松并不是一个独立的预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chemotherapy 医学-药学

CiteScore

5.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal publishes original research articles and state-of-the-art reviews on all aspects of antimicrobial and antitumor chemotherapy. The results of experimental and clinical investigations into the microbiological and pharmacologic properties of antibacterial, antiviral and antitumor compounds are major topics of publication. Papers selected for the journal offer data concerning the efficacy, toxicology, and interactions of new drugs in single or combined applications. Studies designed to determine the pharmacokinetic and pharmacodynamics properties of similar preparations and comparing their efficacy are also included. Special emphasis is given to the development of drug-resistance, an increasing problem worldwide.